Do all patients that undergo a 'complete' secondary cytoreductive surgery for platinum-sensitive recurrent ovarian cancer, benefit from it?
{{output}}
Following the results of three randomized trials (GOG-213, DESKTOP-III, and SOC-1), secondary cytoreductive surgery (sCRS) is recommended as a therapeutic option for all patients with platinum-sensitive recurrence by the NCCN guidelines and for oligometastatic... ...
